The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Maybe, to start out, could you provide some more color on the ex U.S. strategy? Maybe just talk a little bit about the drivers behind the decision
and how you would characterize the discussions that you've had with potential partners.
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Okay. That makes sense. And then maybe just one more -- maybe an update on the IGALMI launch. Have you seen any early adopters in the month
or so since trade launch, and if not, when would you expect the first to start to come on board?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: I have a couple. The first one is on SERENITY III. On the safety aspect, what exactly do you plan to collect in terms of metrics for the at-home use
component?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: And then my follow-up is, given that the label currently does not restrict use of IGALMI to a specific setting, is there anything that precludes a
position from sending a patient home with the film today as things stand?
Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
: I guess, as we think about subsequent quarters where you're going to report revenue, can you just give us any details around how revenue will be
recognized? Is it when order made? Is it when it's shipped? Is it when it's received? So that's question one.
Question two. Sorry if I've missed this, but it looks like TRANQUILITY 2 timing slipped a little from end of this year to first half of next. Just curious
what's the rationale behind this.
And then, third, you -- any details or anything further you can give us on the other assets you're moving into the clinic?
Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
: Okay. Great.
Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
: Just in terms of the -- when do we get more information on your other assets that are somewhat under -- moving stealthily forward?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 09, 2022 / 12:30PM, BTAI.OQ - Q2 2022 BioXcel Therapeutics Inc Earnings Call
| 
